4D Molecular Therapeutics (FDMT)
(Delayed Data from NSDQ)
$23.25 USD
-0.28 (-1.19%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $23.21 -0.04 (-0.17%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Income Statements
Fiscal Year end for 4D Molecular Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 21 | 3 | 18 | 14 | 7 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 21 | 3 | 18 | 14 | 7 |
Selling & Adminstrative & Depr. & Amort Expenses | 134 | 113 | 89 | 70 | 58 |
Income After Depreciation & Amortization | -113 | -110 | -71 | -57 | -51 |
Non-Operating Income | 12 | 3 | 0 | 0 | 1 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -101 | -107 | -71 | -57 | -49 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -101 | -107 | -71 | -57 | -49 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -101 | -107 | -71 | -57 | -49 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -110 | -107 | -69 | -55 | -50 |
Depreciation & Amortization (Cash Flow) | 3 | 3 | 2 | 1 | 1 |
Income After Depreciation & Amortization | -113 | -110 | -71 | -57 | -51 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 39.13 | 32.35 | 27.73 | 6.43 | NA |
Diluted EPS Before Non-Recurring Items | -2.58 | -3.32 | -2.57 | -8.82 | NA |
Diluted Net EPS (GAAP) | -2.58 | -3.32 | -2.57 | -8.82 | NA |
Fiscal Year end for 4D Molecular Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | -0.02 | 20.20 | 0.24 | 0.30 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | -0.02 | 20.20 | 0.24 | 0.30 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 36.63 | 34.18 | 32.37 | 30.40 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -36.65 | -13.98 | -32.13 | -30.10 |
Non-Operating Income | NA | 4.37 | 3.72 | 2.52 | 1.42 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -32.28 | -10.26 | -29.62 | -28.68 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -32.28 | -10.26 | -29.62 | -28.68 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -32.28 | -10.26 | -29.62 | -28.68 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 41.93 | 42.26 | 38.43 | 32.72 |
Diluted EPS Before Non-Recurring Items | NA | -0.77 | -0.24 | -0.77 | -0.88 |
Diluted Net EPS (GAAP) | NA | -0.69 | -0.24 | -0.77 | -0.88 |